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Abstract 
Understanding the link between quality of life and symptoms in schizophrenia is important in 
enhancing the prospect of patient recovery. Only weak associations have been found between 
subjective quality of life (SQOL) and negative symptoms. However, this may be because many 
existing symptom assessment scales inadequately assess the experiential deficits of negative 
symptoms. This study aimed to re-evaluate these findings using the Clinical Assessment Interview for 
Negative Symptoms (CAINS), which as been designed to capture both the expressive and 
experiential subdomains of negative symptoms as separate constructs. In this observational study 
275 participants with at least moderate negative symptoms were assessed three times over nine 
months using the CAINS, the Positive and Negative Syndrome Scale (PANSS), and the Manchester 
Short Assessment of Quality of Life (MANSA). A significant negative association between SQOL and 
the CAINS experiential subscale was found in the cross-sectional analysis (adj. B= -0.28, 95% CI= -
0.44 to -0.12, P=.001), and in the change scores (adj. B=-0.13, 95% CI=-0.26 to -0.01, P=.032). No 
associations between SQOL and expressive symptoms, or negative symptoms measured using the 
PANSS were detected in the multivariable models. These findings suggest that the association 
between negative symptoms and SQOL is related primarily to experiential deficits, and highlights the 
importance of measuring the separate subdomains of negative symptoms as distinct constructs. The 
findings also highlight the impact of negative symptoms and experiential deficits in particular on 
social outcomes, further emphasising the need to develop new treatments for these symptoms. 
1. Introduction: 
For decades there has been a consensus that improving symptoms alone is not a sufficient 
treatment outcome in schizophrenia, with improvements in quality of life seen as central to the 
concept of recovery (Liberman et al., 2002; Priebe, 2007). Lower quality of life has consistently been 
associated with higher negative symptoms of schizophrenia, rather than positive symptoms (Ho et 
al., 1998), however the relationship appears complex. 
Quality of life is recognised to comprise of objective components such as daily life functioning and 
external resources, and subjective components such as wellbeing and satisfaction with life 
(Katschnig, 2000; Lehman et al., 1982; Priebe, 2007). While there evidence of a strong association 
between negative symptoms and objective quality of life (OQOL) (Ho et al., 1998; Hunter and Barry, 
2012; Milev et al., 2005; Whitty et al., 2008), only a weak association between negative symptoms 
and subjective quality of life (SQOL) has previously been found (Eack and Newhill, 2007; Fitzgerald et 
al., 2001; Narvaez et al., 2008; Priebe et al., 2011). This may be because SQOL is determined by 
multiple processes, including the comparison between expectations and aspirations, a comparison 
with others, and adaptation over time, all of which may result in a less negative appraisal by 
individuals with chronic schizophrenia (Priebe, 2007). However, it may also be because the 
relationship has been under-reported due to how negative symptoms have been assessed.  
Negative symptoms include expressive deficits such as blunted affect and alogia, and experiential 
deficits such as asociality, anhedonia and amotivation. There is evidence to to suggest that older 
scales are associated more with expressive deficits (Horan et al., 2011), which may be attributable to 
the fact that such tools rely largely on behavioural referents to measure different negative 
symptoms (Blanchard et al., 2011). One advantage of the newly developed CAINS is that experiential 
and expressive symptoms are separated into distinct subdomains, with a focus on subjective 
experiences of negative symptoms in addition to observed and reported behaviours. 
With this in mind, this study aimed to re-evaluate the link between negative symptoms and SQOL 
using data from one of the largest trials to use the CAINS to date (Priebe et al., 2013). We tested the 
hypothesis that the association between negative symptoms and SQOL will relate exclusvely  to 
experiential deficits, both cross sectionally and over time. We hypothesised that this relationship 
would remain after controlling for depressive symptoms, which is important given the association 
between low mood and SQOL (Eack and Newhill, 2007; Priebe et al., 2011). With evidence to suggest 
that the relationship between SQOL and symptoms may be different between men and women 
(Röder-Wanner and Priebe, 1998), and between those with a long and short illness duration (Priebe 




This is a secondary analysis of data from the NESS Study (ICTRN842165587); a randomised controlled 
trial evaluating the effectiveness of body psychotherapy for schizophrenia. In the study participants 
were randomised to receive either a 20 session Pilates class or body psychotherapy group. 
Assessments were conducted at three timepoints; baseline, end of treatment approximately 3 
months later, and then six months after treatment end. At each stage the CAINS (Horan et al., 2011), 
PANSS (Kay et al., 1987), Manchester Short Assessment of Quality of Life scale (MANSA) (Priebe et 
al., 1999), and Calgary depression scale (Addington et al., 1993) were completed.  
 
2.2.Sample: 
Participants were outpatients with schizophrenia (F20.0-F20.9), presenting with at a score of at least 
18 on the PANSS negative subscale. Further details of the study are described elsewhere (Priebe et 
al., 2013) 
 
2.3. Assessment tools: 
The CAINS (Horan et al., 2011) is a scale designed to address the limitations inherent to previous 
assessment tools used to measure negative symptoms (Blanchard et al., 2011). Although the scale 
can provide a single summary score, the authors recommend reporting the emotional experience 
and emotional expression subscales seperately given the evidence that they are measuring distinct 
constructs (Kring et al., 2013). The scale comprises of 13 items, rated from 0 (no impairment) to 4 
(severe impairment). The first nine items relate to experential deficits, assessing the motivation, 
anticipation and experience of pleasure in occupational and recreational actvities, and social 
contacts with partners, friends and family. The last four items relate to expressive deficits, assessing 
both vocal and gestural features. Evaluations of the tool suggest excellent divergent and convergent 
validity (Kring et al., 2013).  
The PANSS (Kay et al., 1987) is a 30-item semi-structured interview designed to provide an overall 
measure of the symptoms of schizophrenia. Sixteen of the items measure general psychopathology, 
seven positive symptoms of schizophrenia such as hallucinations and delusions, and seven negative 
symptoms. Each item is rated from 1-7, resulting in a range of 7-49 for positive and negative 
symptoms, and 16-112 for general symptoms. In this study the Marder factor solution of the PANSS 
negative subscale was adopted (Marder et al., 1997) which exludes the abstract thinking and 
stereotypical thinking items given they are understood to relate to cognitive deficits (Bryson et al., 
1999). Instead, the active social withdrawal and motor retardation items are included.  
Subjective quality of life was measured by the MANSA (Priebe et al., 1999). The questionnaire 
consists of 16 items; 12 subjective and four objective. The 12 subjective items cover self-rated 
satisfaction of employment, finances, recreational activities, friendships, safety, housing, health, sex-
life, family and overall life satisfaction; scores range from 1 (couldn’t be worse) to 7 (couldn’t be 
better). The four objective items are rated as yes or no, and cover whether they have been a victim 
of a crime, been accused of crime, have anyone they consider a close friend, or have seen a friend in 
the past seven days. A mean total of the 12 subjective items were calculated to create a summary 
score.  
Depressive symptoms were assessed using the Calgary depression scale (Addington et al., 1993), 
which a scale designed specifically for schizophrenia populations. The questionnaire comprises of 
nine items, rated from 0-2, with a higher score indicating higher depressive symptoms. 
 
2.4. Analysis:   
In stage 1 the association between SQOL and expressive deficits, experiential deficits, depression, 
and a summary of the overall negative symptom construct was examined in a univariable regression 
analysis. Any predictors approaching significance (p<.10) were included in a multivariable regression 
model. This analysis was replicated using the three month and nine month follow up data. To assess 
whether there were any differences in the relationship between negative symptoms and SQOL 
between men and women, an interaction term between gender and any significant negative 
symptom variable was added to the multivariable model. To determine whether the relationship is 
different in participants with a long and short duration of illness, a median split of the sample by 
length of illness was performed. An interaction effect between illness duration and any significant 
negative symptom score was then added to the multivariable model.  
In stage 2, longitudinal modelling was used to explore the association between the change in 
negative symptoms and SQOL over time. Symptom change scores were calculated by subtracting i) 
nine month follow up scores (T3) from the three month follow up scores (T2), and ii) three month 
follow up scores (T2) from the baseline scores (T1), resulting in two panels of change-score data. The 
associations between the change scores in SQOL and different measures of negative symptoms were 
then evaluated by way of multi-level modelling, with each change score nested within participants, 
included as a random effect. Significant univariate associations were then analysed in a multivariable 
model, including the change scores of the Calgary scale to control for the association between 
depression and SQOL. Finally, an interaction effect between therapy group allocation and negative 
symptom change was added to the multivariable model where any type of negative symptom 
change was found to be significantly associated to SQOL change. Analyses were conducted using 
STATA version 11.0 (StataCorp, 2009). 
 
3. Results:  
Participants were mostly men (73.8%), with a mean age of 42.2 years (SD=10.65) and a long history 
of illness (mean=13.6 years, SD=9.1). At baseline participants reported low depressive symptoms 
(Calgary mean=4.70, SD=4.37), and moderate negative symptoms (PANSS Marder negative 
mean=22.1, SD=4.8). A total of 275 participants completed the baseline assessment, and 255 the 
final assessment, resulting in a rentention rate of 92.7%. No significant differences were detected 
between completers and drop-outs in the MANSA, CAINS, or PANSS Marder subcales at baseline. 
The inter-rater reliability between the assessors in the CAINS and PANSS was high (PANSS ICC=.85; 
CAINS total ICC=.80).  
Mean values of the CAINS subscales, the PANSS Marder negative subscale and the MANSA are 
presented in Table 1. A small, significant reduction over time was detected in the CAINS expression 
subscales, and the PANSS Marder negative subscale. A slight improvement in SQOL over time was 
also detected, however this was not significant. 
[INSERT TABLE 1 HERE] 
The associations between negative symptoms and SQOL are reported in Table 2. At baseline a 
significant negative association was found between SQOL and the CAINS experiental subscale, 
explaining 8.3% of the variance (B=-0.43, 95% CI=-0.62―-0.25, P<.001. R2=.083). No association was 
detected between the SQOL and the PANSS Marder negative subscale (B=-.01, 95% CI=-0.34―0.01, 
P=.356. R2=.003) or the CAINS expression subscale (B=-0.10, 95% CI=-0.02―0.20, P=.103. R2=.010). A 
strong significant negative association between depressive symptoms and SQOL was detected, 
explaining 24.1% of the variance (B=-.38, 95% CI= -0.46―-0.30, P<.001, R2=.241). 
In the multivariable analyses, a significant negative association was detected between experiential 
symptoms and SQOL, after controlling for depressive symptoms (adj. B= -0.28, 95% CI -0.44―-0.12, 
P=.001). The negative associations between experiential deficits and SQOL were consistent both at 
three months (adj. B=-0.19, 95% CI=-0.36―-0.02, P=.036) and nine months follow-up (adj. B=-0.23, 
95% CI=-0.37―-0.08, P=.003). The relationship between experiential symptoms and SQOL was not 
significantly different between participants with a short and long illness duration (adj. B= -0.08, 95% 
CI= -0.43―-0.27, P=.671), or between men and women (adj. B=0.29, 95% CI -0.11―-0.68, P=.152).  
[INSERT TABLE 2 HERE] 
Over time, a negative association was detected between SQOL and experiential symptoms (B=-0.21, 
95% CI= -0.34―-0.09, P=.001), depressive symptoms (B=-0.04, 95% CI= -0.05―-0.02, P<.001), and 
the PANSS Marder negative subscale (B=-0.02, 95% CI= -0.03―0.00, P=.044). No significant 
association was detected between the changes in expressive symptoms and SQOL. In the 
multivariate analysis, a significant negative association between depressive symptoms (adj. B=-0.03, 
95% CI= -0.05―-0.01, P=.014), and experiential symptoms (adj. B=-0.19, 95% CI= -0.31―-0.04, 
P=.008) was detected. The relationship between the PANSS Marder negative subscale and SQOL was 
no longer significant (adj. B=0.00, 95% CI= -0.02―0.02, P=.882). 
In the sensitivity analysis an interaction effect between change in experiential symptoms and 
therapy group allocation was added to the multivariable model. While there was a trend toward the 
relationship being stronger in the Pilates rather than body psychotherapy condition, this was not 
significant (adj. B= 0.21, 95% CI=-0.04―0.46, P=.100).   
 
4. Discussion: 
4.1. Main findings: 
The findings indicate that the relationship between SQOL and negative symptoms relate exclusively 
to experiential deficits. A significant negative association was detected between SQOL and the CAINS 
experiential subscale at all three time points assessed. Over time, again only the experiential 
features of negative symptoms were found to be a significant predictor of SQOL change. No 
relationship was found between either SQOL and the CAINS expressive subscale, or the PANSS 
negative subscale in the multivariable model. These findings suggest that some scales under-report 
the relationship between SQOL and negative symptoms, either by inadequately assessing 
experiential symptoms or examining negative symptoms as a singular construct.  
 
4.2. Strengths and weaknesses: 
The data came from a large trial with excellent study retention rates. This dataset is one of the 
largest to use the new CAINS assessment tool to date, with a sufficient number of participants to 
interpret non-significant associations as evidence of no effect. The inter-rater reliability between the 
assessors on both the PANSS and the CAINS was high. In the sensitivity analyses the findings were 
the same at all three time points, consistent between men and women, those that reported a long 
and short duration of illness, and between the therapy intervention groups, suggesting the findings 
are robust. The association between experiential symptoms and SQOL was found to be consistent in 
the multivariable analysis which controlled for depressive symptoms, indicating that the relationship 
detected is not attributable to low mood. The fact that significant associations were only detected 
between experiential symptoms and SQOL, and not expressive symptoms or negative symptoms as 
measured as a singular construct suggests that the relationship detected was not a consequence of 
common method variance.  
The main limitation of the study relates to a possible selection bias. All participants reported at least 
moderate levels of negative symptoms at baseline, so it is unclear whether these findings would be 
replicated in participants with lower negative symptoms. In addition, most participants reported a 
long duration of illness, which may be an issue given the impact of symptoms on SQOL is more 
prominent in the early stages of illness (Browne et al., 2000). In this study no significant difference 
was detected between participants with a long and short illness duration. However, 90% of 
participants reported an illness duration of at least 4 years, so it is unclear whether these 
relationships would be consistent in recent onset patients.  
 
4.3. Comparison with the literature: 
While the relationship between negative symptoms of schizophrenia and SQOL has been examined 
previously, to our knowledge this is the first time the link between SQOL and expressive and 
experiential deficits as separate constructs have been considered. The association between 
experiential deficits and SQOL appears to be significantly stronger than in previous studies which 
have examined the relationship to negative symptoms as a singular construct (Eack and Newhill, 
2007; Narvaez et al., 2008; Priebe et al., 2011). In contrast to previous studies, the association 
between changes in experiential deficits and SQOL over time remained significant after controlling 
for depression (Priebe et al., 2011). 
The reason why experiential symptoms in particular are associated with lower SQOL merits further 
investigation. Regarding anhedonia, people with schizophrenia report impairments in anticipatory 
and trait assessments of  pleasure (Gard et al., 2007; Horan et al., 2006), which may impact how an 
individual reports their life satisfaction. Hedonic deficits are also significantly associated with health-
related quality of life (Ritsner et al., 2011). With amotivation, evidence suggests that motivational 
deficits may be an important determinant of functional disability (Konstantakopoulos et al., 2011; 
Reddy et al., 2015), possibly attributable to difficulties in perceiving reward outcomes (Gard et al., 
2014), and effort-based decision making (Horan et al., 2015). This argument is supported by the 
recent finding that amotivation, but not expressive deficits, have been found to be associated with 
impairments in integrating rewards with effortful behaviour during decision making (Hartmann et 
al., 2015).  Asociality is likely to result in a larger degree of isolation from others, and impair their 
ability to adequately function in their social context. Taken together, these symptoms could all effect  
SQOL directly in a way that expressive deficits may not. 
These findings support the argument that experiential and expressive symptoms represent distinct 
subdomains (Blanchard and Cohen, 2006), and as such should be measured separately (Horan et al., 
2011). Assessing the symptoms in this manner may better resemble the negative symptom construct 
as it is currently understood, and may yield new insights which have previously been undetected. 
This study lends support to a model proposed by Priebe (Priebe, 2007), which suggests that QOL 
could be improved by treatment indirectly via improvements in symptoms. As noted by Reddy 
(Reddy et al., 2015), there has been a recent focus on developing new treatments designed 
specifically to target experiential symptoms, given their impact on functional disability. The findings 
of the current study suggest that such a focus may also be important to improving the SQOL of 
patients with schizophrenia. 
 
4.4. Conclusion: 
The link between SQOL and negative symptoms appears to relate exclusively to experiential deficits. 
These findings highlight the importance of assessing the experiential and expressive subdomains of 
negative symptoms as separate constructs, and support the model which proposes that an 
improvement in symptoms can indirectly result in improvements in SQOL. The findings also highlight 
the importance of treating negative symptoms, and experiential deficits in particular, given their 
impact of social outcomes. Interventions designed specifically to improve experiential deficits should 
be the focus of both treatment and research if the aim is to improve SQOL as part of a wider 
programme to support patient recovery. 
 
  
Table 1: Mean scores and change over time. 
       
 
T1  T2 T3 
 
F P 
Variable Mean SD Mean SD Mean SD 
 
          MANSA SQOL 4.44 0.93 4.58 0.89 4.52 0.95 
 
1.51 .221 
PANSS Negative (Marder) 22.07 4.83 20.51 5.43 20.13 5.61 
 
10.07 <.001 
CAINS Expression  1.94 0.92 1.85 0.98 1.78 1.04 
 
1.76 .174 
CAINS Experience 2.42 0.62 2.24 0.64 2.29 0.71 
 
4.92 .008 
Calgary Depression scale 4.69 4.36 3.92 4.30 4.11 4.15 
 
2.37 .094 
              
 
  
SD= standard deviation; SQOL subjective quality of life; T1= baseline; T2= 3 months follow up; T3= 9 months follow 
up 
  
Table 2: Associations between negative symptoms, depression and SQOL   





    B SE B 95% CI P R² 
 
Adj. B SE B 95% CI P 
              Cross-sectional associations with SQOL at baseline 
                        
 
CAINS Experiential subscale -0.43 0.09 -0.62 -0.25 <.001 .083 
 
-0.28 0.08 -0.44 -0.12 .001 
 
CAINS Expressive subscale 0.10 0.06 -0.02 0.22   .103 .010 
 
- 
    
 
PANSS Negative subscale -0.01 0.01 -0.03 0.01   .356 .003 
 
- 
    
 
Calgary Depression Scale -0.38 0.04 -0.46 -0.30 <.001 .241 
 
-0.35 0.04 -0.43 -0.27 <.001 
 
       
 
     
Associations between changes over time with SQOL 
    
 
     
              
 
CAINS Experiential subscale -0.21 0.06 -0.34 -0.09   .001 
 
 
-0.18 0.07 -0.31 -0.04 .008 
 




    
 
PANSS Negative subscale -0.02 0.01 -0.03 -0.00   .044 
 
 
0.00 0.01 -0.02 0.02 .882 
 
Calgary Depression Scale -0.04 0.01 -0.05 -0.02 <.001 
 
 
-0.03 0.01 -0.05 -0.01 .014 
                          
SQOL= Subjective Quality of life; B= Beta coefficient; SE= Standard error; CI confidence interval 
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